Company Overview: PixarBio

Industry News

13 Feb

PixarBio Corporation to Attend and Discuss NeuroRelease™ a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 BIO CEO & Investor Conference in NYC, NY, February 13-14, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation (PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in late 2018 for our 14-day post-surgical pain treatment, announced today that it will be attending the BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New...

Read more

23 Jan

PixarBio Corporation Terminates InVivo Therapeutics Bid

CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation, (PXRB) today announced that we will stay focused on our NeuroRelease Pain platform and continue to drive our non-opiate non addictive morphine replacement to market with FDA approval expected between the end of 2018 and early 2019. PixarBio has an IP portfolio covering pain,...

Read more

19 Jan

SeeThruEquity Issues Update on PixarBio Corporation (OTCQX: PXRB)

NEW YORK, NY / ACCESSWIRE / December 19, 2016 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has issued an update note on PixarBio Corporation (PXRB). The report is available here: PXRB Update Note. Based in Cambridge, MA, PixarBio...

Read more

5 Jan

PixarBio Corporation CEO Frank Reynolds to Present NeuroRelease™ a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 Biotech Showcase in San Francisco, CA on Tuesday, January 10th at 10am PST

CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation, (PXRB) developers of NeuroRelease™, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in early 2019, announced today that its Chief Executive Officer and Chief Science Officer Frank Reynolds will present at the Biotech Showcase 2017 held in San Francisco, CA on...

Read more

5 Jan

PixarBio Corporation Entered into an Agreement with Henry Sargent, to Sell to Him All of the Membership Interests in PixarBio’s Wholly Owned Subsidiary Buddhi Mat LLC

CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation, (PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opiod, non-addictive pain treatment with FDA approval expected in early 2019, announced today, that on Friday, December 30, 2016, it sold to Henry Sargent all of the membership interests in Buddhi Mat LLC, the Company’s wholly owned...

Read more

4 Jan

PixarBio Corporation Responds to InVivo Therapeutics False Patent and Intellectual Property Claims

CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation, (PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in early 2019, announced a response to InVivo Therapeutics press release dated January 3, 2017. The press release claims that, “InVivo has an exclusive license in the field of...

Read more

3 Jan

It’s Time to Make US Pharma GREAT Again, By Combining Two Frank Reynolds’ Founded Pharmas, PixarBio Corp (OTCQX:PXRB) and InVivo Therapeutics (NASDAQ:NVIV)

CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation, (PXRB) today announced a take-over bid to acquire InVivo Therapeutics the company PixarBio CEO Frank Reynolds founded in 2005. The deal is expected to close in Q1 2017. PixarBio Board of Directors has approved the offer, Board member Derek Bridges explained “As a Board,...

Read more

21 Dec

PixarBio Corporation Establishes the JP Reynolds Research Center in Woburn, MA to Advance In-house Research Portfolio in Epilepsy, Spinal Cord Injury, and Non-Addictive Pain Platform

CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation, (PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in early 2019, announced today that it has established the JP Reynolds Research Center in Woburn, MA to transfer neurological research toward market. The lab will focus on R&D...

Read more

20 Dec

PixarBio Corporation Names Steve Chartier Chief Operating Officer, To Lead Regulatory Affairs, CMC, and Clinical Studies for NeuroRelease™ a Morphine Replacement, Non Addictive Pain Treatment

CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation, (PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in early 2019, announced today that Steve Chartier PixarBio VP of Regulatory Affairs has been named PixarBio’s Chief Operating Officer (COO). “Steve has been a constant contributor to PixarBio’s...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address